About the Authors
- Richard A. Adegbola
-
* E-mail: richard.a.adegbola@gsk.com
Affiliation GlaxoSmithKline Vaccines, Wavre, Belgium
- Rodrigo DeAntonio
-
Affiliation GlaxoSmithKline Vaccines, Wavre, Belgium
- Philip C. Hill
-
Affiliations Medical Research Council Unit, Banjul, The Gambia, Centre for International Health, School of Medicine, University of Otago, Dunedin, New Zealand
- Anna Roca
-
Affiliation Medical Research Council Unit, Banjul, The Gambia
- Effua Usuf
-
Affiliation Medical Research Council Unit, Banjul, The Gambia
- Bernard Hoet
-
Affiliation GlaxoSmithKline Vaccines, Wavre, Belgium
- Brian M. Greenwood
-
Affiliation Faculty of Infectious & Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
Competing Interests
Drs. Philip C. Hill, Anna Roca, and Effua Usuf have no conflicts of interest to declare. The institution that employs Dr. Brian M. Greenwood received a grant from PATH to support a clinical trial of a pneumococcal protein vaccine produced by GlaxoSmithKline and Dr. Greenwood has received travel fees for meetings related to this trial. Drs. Richard A. Adegbola, Rodrigo DeAntonio, and Bernard Hoet are employees of the GlaxoSmithKline group of companies and declare ownership of GlaxoSmithKline shares and stock options. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. This manuscript is a systematic review and all included references are publicly available.
Author Contributions
Conceived and designed the experiments: RAA AR BMG. Analyzed the data: RAA RD. Wrote the paper: RAA RD PCH AR EU BH BMG.